According to the Zhitong Finance App, Tiger Pharmaceuticals (03347) announced the results for the first three quarters of 2026. The group achieved operating income of 5.792 billion yuan in the first three quarters, an increase of 15.23% over the previous year; a net loss of 272 million yuan to the mother, a year-on-year profit and loss; and a basic loss of 0.32 yuan per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.